Vimarsana
Biggest News Aggregation in the World

Page 7 - Rx Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rx Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rx Communications Today - Breaking & Trending Today

ReShape Lifesciences to Present at the Q4 Investor Summit - Vimarsana News

ReShape Lifesciences to Present at the Q4 Investor Summit

SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health...

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING - Vimarsana News

THERMOGENESIS CLOSES $2.05 MILLION PUBLIC OFFERING

/PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous...

THERMOGENESIS PRICES $2.05 MILLION PUBLIC OFFERING - Vimarsana News

THERMOGENESIS PRICES $2.05 MILLION PUBLIC OFFERING

/PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the "Company"), a market leader in automated cell processing and point-of-care, autologous...

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing - Vimarsana News

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing

/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects,...

Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-Raf Inhibitors in MEK Inhibitor induced rash - Vimarsana News

Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-Raf Inhibitors in MEK Inhibitor induced rash

/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects,...